Abeona Therapeutics (ABEO) ABO-102 Data is a 'Promising Start' - Cantor Fitzgerald

October 20, 2016 10:21 AM EDT
Get Alerts ABEO Hot Sheet
Price: $5.85 -1.68%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 18 | New: 18
Trade ABEO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating and $21 price target on Abeona Therapeutics (NASDAQ: ABEO) after the company reported initial 30-day data from three Sanfillipo Type A (MPS IIIA) patients treated with its gene therapy candidate ABO-102 (AAV-SGSH) at a low dose of 5E12vg/kg.

Piros calls it a 'promising start': "A one-time treatment with ABO-102 resulted in mean reductions in CSF gylocosaminoglycan (GAG)-levels of 25.6% + 0.8% and urine GAG decrease of 57.6% + 8.2% within one month. Moreover, these patients had liver and spleen reductions of 17.1% + 1.9% and 17.6% + 7.1%, respectively, as determined by MRI. As a reminder, the three patients were enrolled initially into a MPS IIIA natural history study in which patients had an average liver and spleen enlargement of 116% and 88%, respectively. This enlargement remained unchanged at the time of rollover into the Phase 1/2 study."

For an analyst ratings summary and ratings history on Abeona Therapeutics click here. For more ratings news on Abeona Therapeutics click here.

Shares of Abeona Therapeutics closed at $7.76 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Cantor Fitzgerald

Add Your Comment